PARTICIPANT INFORMATION SHEET & INFORMED CONSENT FORM

Study Name:	Pharmacokinetics of Intramuscular Versus Subcutaneous Administration of Benzathine Penicillin G (Bicillin L-A)
Protocol No:	U1111-1216-5903
Study Sponsor:	Telethon Kids Institute
Study Site:	Linear Clinical Research
Study Doctor:	Associate Professor Laurens Manning

You are being invited to take part in a research study. This is because you are male and aged 18 to 65 years of age and in good general health. This Participant Information Sheet & Informed Consent Form has information to help you decide if you want to participate.

Take your time, read this form carefully, and ask the study doctor or staff any questions you may have, and to explain any words, terms, or sections that are unclear to you. You should not sign this form until you understand all of the information presented in the following pages and until all of your questions about the research study have been answered to your satisfaction.

Your participation in this study is entirely voluntary and you may withdraw at any time. If you decide to participate in this study, you can then choose to stop taking part in the study at any time for any reason. If you refuse to participate in the study or stop being in this study, it will not affect your care or treatment outside this study, payment for your health care, or your health care benefits. You are encouraged to discuss the study with your family, friends and GP, should you have one, prior to signing consent.

The institution (Linear Clinical Research Ltd.) will be paid by the Sponsor, Telethon Kinds Institute for conducting this study.

About This Study

Pfizer has developed Benzathine Penicillin G (BPG - the study drug), for the treatment and prevention of recurrent episodes of acute rheumatic fever (ARF), and has been in use since the 1950s. ARF is an illness caused by an autoimmune response to a bacterial infection with group A streptococcus. ARF typically develops 2-4 weeks after a streptococcal throat infection and symptoms include joint swelling and pain, fever, uncontrolled movements, and skin rash. In addition, ARF can lead to damage of the heart valves, also known as rheumatic heart disease (RHD). RHD affects an estimated 33.4 million people worldwide, resulting in the death of approximately 319,400 people each year. In Northern Australia, Indigenous populations are particularly affected.

BPG is marketed in Australia as Bicillin®L-A, and is a penicillin antibiotic that has been approved by the Therapeutic Goods Administration (TGA) for the treatment of infections such as streptococcal infections, infections of the upper respiratory tract, syphilis, and some skin diseases.

Bicillin®L-A is typically given as a deep intramuscular (IM) injection. IM injection is a procedure which delivers a medication deep into the muscles, for quick absorption into the bloodstream. However, there is often a lack of compliance in completing the required course of injections. It is thought that by administering Bicillin®L-A as a subcutaneous injection (SC – under the skin) it may increase the rate of compliance.

The purpose of this research study is to test the pharmacokinetics (PK – how your body takes in and disposes of the study drug) as well as the tolerability of Bicillin®L-A when administered as an IM and SC injection. We are doing this study in healthy men to find out:

- How much of the drug gets into the bloodstream, and how long does the body take to get rid of it when administered as a SC and IM injection.
- Does the drug have any side effects when administered as a SC and IM injection.
- To measure the level of pain caused by the injection of the study drug when administered as a SC and IM injection.

This study will look at how participants react to and how the human body uses Bicillin®L-A when administered as a SC and IM injection.

The design of the study is single-blind, randomised and 2x2 crossover.

A single-blind study means that only the study doctor will know which way the study drug is administered (IM or SC injection) in each participant. The participants who take part will not know which way the study drug is administered. This way, the effects reported by all participants will be treated equally.

A 2x2 crossover means that you will receive a sequence of different treatments. In this study one group of participants (Group A) will receive the study drug via IM injection (Period 1) followed by a second dose of the study drug via SC injection (Period 2), with a washout period between each dose. In Group B, participants will receive the study drug via SC injection (Period 1) followed by a second dose of study drug via IM injection (Period 2), with a washout period between each dose.

To be randomised means that a computer will allocate by chance which Group you will be in. Neither you nor the study doctor can choose which Group you are randomised to.

We will be testing a single dose of the study drug in a total of 15 healthy volunteers who will be divided into 2 groups. The following will be the way that the groups are planned to be dosed for the study:

Cohort	Number of Participants Dosed	Administration Route		Total Dose of Bicillin®L-A	Injection Volume
		Period 1	Period 2		
A	7	IM	SC	1016.6 mg	2.3 mL
B	8	SC	IM	1016.6 mg	2.3 mL

The study drug will be administered via an intramuscular (IM) or subcutaneous (SC) injection into the buttock over a period of 3 minutes. You will be required to lie flat on your stomach and will nominate which buttock to use for the first administration (Period 1). For the second administration (Period 2) the opposite buttock will be used. An ultrasound will be used to guide the injection and confirm the injection site.

This study is being conducted by Linear Clinical Research. The study is being sponsored by the Telethon Kids Institute.

Your GP and/or specialist, should you have one, will be notified of your participation in this study and of any clinically relevant information noted by the study doctor during the course of the study. Your GP may also be contacted to obtain information regarding your medical history.

What will I be asked to do?

If you choose to take part in this study and it is determined you are eligible and able to participate, your length of involvement would be up to approximately 20 Weeks (this includes a 14-day screening period, two 6-week administration periods, separated by a 4-week washout and a follow-up phone call 2-weeks after completing the second administration period). During your stay at the clinic, all meals and refreshments would be provided for you, so please inform the staff if you have any special dietary requirements.

Additional volunteers will be recruited and admitted to the unit as alternates. If you are an alternate, you may be asked to participate in the study if someone drops out. You will be informed if you are an alternate before admission. Please note that if you are deemed eligible following the screening visit, this will not automatically mean you will be included in the study, with additional eligibility checks needing to occur on the morning prior to dosing on Day 0. If you have been admitted as an alternate you will be advised that you will not be required once dosing has been completed for the group on the morning of Day 0. You will then be discharged from the clinic.

What will happen during the study visits?

Please refer to the Schedule of Assessment for additional information on page 8.

Screening Visit (Up to 2 weeks prior to Period 1 Day 0; visit should be about 2-3 hours)

This visit will involve:

- A discussion with the study doctor to make certain you fully understand the study, its procedures and requirements. Please make sure you ask any questions you may have about the study before or during this visit. You will need to sign the attached Informed Consent Form to confirm you are willing to participate in this study and follow all instructions provided by the study staff, as well as abide by any study restrictions (these are detailed in the 'What are my responsibilities in this study' section).
  Please note that you are receiving this participant information sheet and consent form prior to coming into the clinic for the screening visit. This is to allow you to review the information and discuss your potential involvement in this study with family, friends and or a medical professional of your choosing (such as your GP). After signing the consent form in the presence of the study doctor you will have the opportunity to leave the clinic and come back at a later time, to complete the screening visit assessments outlined below, should you wish to discuss your involvement further with friends, family or a medical professional of your choosing.
- Following your consent you will undergo a complete medical examination which will include:
  - Documentation of demography (race, gender, ethnicity);
  - Medical/surgical history;
  - A full physical examination will be done. Your overall health will be assessed which may include assessment of your general appearance, head, eyes, ears, nose, throat, neck, lymph nodes, neurological and musculoskeletal systems, heart, lungs, and abdomen. This will include measurement of your height and weight. You may be asked to lift or remove your clothing to gain access to your chest for examination of heart and lungs. This will be performed behind a closed curtain for your privacy.
  - Vital sign measurements (blood pressure, pulse rate and temperature).
- You will be asked about a history of drug and alcohol use, and any medications that you are taking, or any other products that you are currently using, as some medications must not be taken before or during the study (please refer to the 'What are my responsibilities in this study' section for this information).
- You will be required to give a urine sample which will be used to perform tests to assess your general health, including screening for drugs of abuse. Please note you will not be eligible to participate in this study if you return a positive test result.
- Breathalyser samples for alcohol use will be obtained, please note you will not be allowed to participate in the study if you return a positive result.
- You will be asked how you are feeling. Please make sure you tell study staff as much information as possible.

- A sample of blood (approximately 15 mL, or 3 teaspoons) will be taken from a vein in your arm with a needle and syringe – this will be used to perform tests to assess your general health.
- In order to take part in the study, you must agree to have specific blood tests for Hepatitis B, Hepatitis C and Human Immunodeficiency Virus (HIV). Approximately 5 mL, or 1 teaspoon of blood, will be taken for this testing (included in the volume above). You will receive information and counselling before the test. If a positive result is found as a result of this testing, appropriate counselling services will be arranged by the study doctor to discuss treatment options. There is also an obligation by study staff, to notify the WA Department of Health. Please note you will not be eligible to participate in this study if you return a positive test result.
- At the conclusion of the screening visit, provided you are eligible and willing to participate in the study, a study staff member will contact you and explain the details of the study to you, including re-confirming the study dates and restrictions.
- There may be reasons why you are not allowed to take part in this study. The study doctor or staff will discuss these with you.

Day 0 – **(Dosing Day - Administration Period 1 and 2; visit should be about 15 hours)**

You will check in to the Linear study clinic on the morning of Day 0, and will undergo the following procedures (please note there is no requirement for you to fast prior to study drug administration):

- Review of your ongoing eligibility to participate in the study (including recording of any new medications taken since your screening visit).
- You will be asked how you are feeling and if you had any changes in your health since your screening visit. It will be very important to tell the study staff about anything that has changed so that it can be properly recorded before you have any study medication. These changes won't necessarily keep you from continuing in the study, so please make sure you tell study staff as much information as possible.

Participants who remain eligible will undergo the following:

- A urine sample will be collected which will be used to perform tests to assess your general health, including screening for drugs of abuse. Please note you will not be eligible to participate in this study if you return a positive test result.
- Breathalyser samples for alcohol use will be obtained, please note you will not be allowed to participate in the study if you return a positive result.
- Measurement of your vital signs.
- Pre-dose blood samples (approximately 10 mL or 2 teaspoons) will be taken for tests to assess your general health.
- An additional sample of blood will be collected via a finger prick for research purposes (dried blood spot PK sample).

- You will be randomised to receive the study drug via IM (Group A) or SC (Group B) injection on the morning of Day 0 (Period 1 only). You will be provided with a randomisation number which will indicate how the study drug is to be administered, but this information will not be shared with you.
- You will then be asked to lie flat on your stomach and the study drug will be administered into the nominated buttock over a period of 3 minutes. An ultrasound will be used to guide the needle and confirm the injection site.

After study drug administration you will then undergo the following:

- You will be asked how you are feeling and if you have had any changes in your health since dosing.
- Your vital signs will be measured 2, 6 and 12 hours after dosing.
- Blood samples (approximately 4 mL, or a little less than 1 teaspoon) will be taken 12 hours after dosing to assess your general health and for research purposes (PK sample – for comparison with dried blood spot sample).
- A blood sample will be collected via a finger prick for research purposes (dried blood spot PK sample) 2, 6 and 12 hours after dosing.
- A pain assessment will be performed using the numeric rating scale (NRS), where you will be asked to rate your pain level. You will also be asked to describe the type of pain you experience by using the phrases “throbbing”, “dull”, or “sharp” and whether the pain prevents you from undertaking normal activities. E.g. walking. The pain assessment will be performed straight after dosing and then at 2, 6 and 12 hours after dosing.
- You will be asked how you are feeling at regular intervals after dosing. Please make sure you let the study staff know if there are any changes in how you are feeling at any point of the study.
- If the study doctor approves, you will be checked out of the clinic after completion of the 12-hour post dose assessments and can return home. Please make sure you let the study doctor or study staff know of any symptoms you may be feeling before leaving the clinic, so the study doctor can properly assess you before you leave.

<u>Day 1, 2, 3, 5, 7, 14, 21, 28 and 42</u> **(Period 1 & 2; *visit will be approximately 1-2 hours*)**

You will have follow-up visits on Days 1, 2, 3, 5, 7, 14, 21, 28 and 42. These visits will take place at the Telethon Kids Institute in Subiaco, and the study team will provide you with directions on how to get there. You will undergo the following assessments:

- You will be asked how you are feeling and if you have had any changes in your health and whether you have taken any other medications.
- A blood sample will be collected via a finger prick for research purposes (dried blood spot PK sample).

- **Days 1, 2 & 3 only:** A pain assessment will be performed using the numeric rating scale (NRS), where you will be asked to rate your pain level. You will also be asked to describe the type of pain you experience by using the phrases “throbbing”, “dull”, or “sharp” and whether the pain prevents you from undertaking normal activities. E.g. walking. NOTE: Additional pain assessments may be performed if pain was recorded at the previous visit.
- **Days 1 & 2 only:** You will be asked if you have experienced any side effect around the injection and site and a visual assessment of erythema (redness of the skin) and irritation will be performed by the study doctor. If erythema or irritation is present the area will be measured. NOTE: Additional assessments may be performed if pain or irritation was recorded at the previous visit.
- **Day 14 only:** A blood sample (approximately 4 mL, or a little less than 1 teaspoon) will be taken for tests to assess your general health and for research purposes (PK sample – for comparison with dried blood spot sample).
- **Day 28 only:** An ultrasound of the injection area will be performed to assess any changes to the area.

Washout Period (4 weeks)

After completing Period 1, you will undergo a washout period of at least 28 days prior to commencing Period 2.

Period 2

You will again check in to the Linear Clinical Research Ltd. clinic on the day of dosing (Period 2 Day 0) which will be approximately 4 weeks after completing Period 1. All procedures will be completed as they were for Period 1.

For Period 2, participants will receive a second dose of the study drug in the opposite buttock via SC (Group A) or IM (Group B) injection, under the same conditions as Period 1.

Telephone follow-up (2 weeks after completing Period 2)

2 weeks after completing Period 2, you will be contacted by the study team and will be asked how you are feeling and if you have had any changes in your health.

Study Schedule of Assessments

	Screen	Period 1 and Period 2														Washout Period	Follow-up Period
	2 weeks	Day 0					Day 1	Day 2	Day 3	Day 5	Day 7	Day 14	Day 21	Day 28	Day 42	4 weeks	14 Days after Completing Period 2
Event ▼ Study Hour ▶		Pre-dose	0 h	2	6	12	24	48	72								
Informed Consent	X																
Inclusion/Exclusion Criteria	X	X															
Demographics																	
Medical History	X																
Height	X																
Physical Exam (incl. weight)	X																
Vital Signs	X	X		X	X	X											
Clinical Laboratory Tests	X	X															
HIV, Hepatitis B/C Testing	X																
Urine Drug / Alcohol Breath Test	X	X															
Dried Blood Sampling PK Sample		X		X	X	X	X	X	X	X	X	X	X	X	X		
PK Blood Sample (from a vein)						X						X					
Pain Score			X	X	X	X	X	X	X	X*	X*	X*	X*	X*	X*		
Monitoring of Skin Irritation							X	X	X*	X*	X*	X*	X*	X*	X*		
Ultrasound Scan of Injection Site			X											X			
Study Medication Administration			X														
Adverse Events		◄	—	—	—	—	—	—	—	—	—	—	—	—	—	—	►
Record Current Medications	◄	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	►
In Clinic Confinement		◄	—	—	—	►											
Outpatient Visit	X						X	X	X	X	X	X	X	X	X		
Telephone Call Follow-up																	X

* Assessments performed only if pain or irritation was recorded at the previous visit

What are my responsibilities on this study?

The following things are important during your participation in this study:

- You will not be permitted to take any prescription medications or over the counter medication (including vitamins, herbal products and supplements) within 7 days prior to dosing until completion of the final follow-up visit.
- You must not take any other penicillin-based antibiotics during the study period. You must also not take Probenecid or any non-steroidal anti-inflammatory medication (NSAIDs) within 14 days prior to dosing, other than paracetamol and ibuprofen.
- Please inform the study doctor of any medications, including herbal, vitamin, over the counter or prescription you have taken in the month prior to the expected dosing day, as these will need to be recorded and will help to determine your eligibility for study participation.
- You must not have smoked or used any tobacco containing products within 1 month prior to screening, and must be willing to not smoke during your stay at the Linear study clinic.
- You must not have any prior documented allergy to penicillin, soy and cephalosporin antibiotics.
- You must not have history of asthma, kidney or liver disease.
- You must be willing to have no alcohol within 24 hours of the screening visit.
- You must not have participated in any other clinical trial within 3 months prior to screening.
- You must report any changes in the way you are feeling to the study doctor or study staff at any point throughout the study**.**

What effects could the tests have on me?

Blood Collection: There is some slight discomfort involved in taking blood with a needle and syringe or via a finger prick. The collection of blood from a vein is usually very safe, but there are potential risks associated with this. There is a small risk of infection, although the use of antiseptic solutions prior to insertion of the needle minimises this risk. There is the possibility of bruising and discomfort around the site of the needle insertion, although this is generally minor and resolves within a few days.

Procedures relating to blood collection can also occasionally cause light-headedness or fainting. These reactions are usually mild, of short duration and limited to a feeling of weakness, accompanied by sweating, slowing of heart beat, and a decrease in blood pressure.

What are the possible risks of the Study Drug?

Benzathine penicillin G (BPG) has been used since the 1950s, and is approved in Australia by the Therapeutic Goods Administration (TGA) as Bicillin® L-A for the treatment of Acute Rheumatic Fever (ARF). Between September 1997 and May 2014, approximately of 206,410 doses of Bicillin® L-A were prescribed, with the most common side effects reported being pain, redness and localised swelling at the injection site.

The following information provides a list of potential side effects which have been reported with the use of Bicillin® L-A:

Common side effects (between 1 in 10 and 1 in 100 people are affected)

- Injection site reactions (pain, redness, swelling)
- Diarrhoea
- Nausea
- Allergic reaction

Uncommon side effects (between 1 in 100 and 1 in 1,000 people are affected)

- Vomiting

Rare side effects (between 1 in 1,000 and 1 in 10,000 people are affected)

- Somnolence (sleepiness)

Very rare side effects (less than 1 in 10,000 people are affected)

- Death

Side effects with unknown frequency

- Skin eruptions (rash)
- Urticaria (hives – itchy, red skin rash)
- Oedema (fluid build-up in tissue)
- Fever
- Low blood counts
- Chills
- Arthralgia (joint pain)
- Neuropathy (numbness/ tingling sensation)
- Fatigue
- Pruritus (itching)
- Headache
- Dizziness
- Diaphoresis (sweating)
- Hypotension (low blood pressure)
- Hypertension (high blood pressure)
- Vasovagal reaction (fainting)
- Heart palpitations
- Tachycardia (abnormally fast heart rate)
- Asthenia (lack of energy)
- Dyspnoea (shortness of breath)

Benzathine penicillin G (BPG) has also been associated with Hoigne's Syndrome which is reaction which has been reported after administration of BPG. Symptoms of Hoigne's Syndrome include severe agitation, confusion, visual and auditory hallucinations, and a fear of impending death. Other symptoms associated with this syndrome include psychosis, seizures, dizziness, tinnitus (ringing in the ears), cyanosis (blue tinge to the skin caused by a lack of oxygen), palpitations, tachycardia and abnormal perception in taste.

Additional information related to the use of Bicillin® L-A will be provided to you in the Consumer Medicines Information (CMI) sheet.

Linear's clinical facility is fully equipped with a crash cart (an emergency care trolley) and all staff are trained to deal with medical emergencies. In addition to appropriate first aid supportive measures by clinical and medical staff at Linear, your treatment may include the administration of various drugs, which may include adrenaline, anti-histamines or hydrocortisone. The Sir Charles Gairdner Hospital Emergency Department will also be contacted if required.

Are there pregnancy risks?

Previous human experience with penicillins during pregnancy has not shown any evidence of side effects on the foetus. BPG is classed as pregnancy Category A drug in Australia, meaning it has been taken by many pregnant women and women of child-bearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded.

It is recommended that male participants with a female partner of child-bearing potential, use a condom for all sexual intercourse for the entire duration of the study until completion of the follow-up visit.

It is highly recommended that you inform your partner of your participation in the study. You should advise your study doctor if you father a child while participating in the research project. Your study doctor will advise on medical attention for your partner should this be necessary.

You will be told in a timely manner about significant new information that might affect your decision to stay in the study.

What happens to my blood samples that are collected?

During the study, the estimated total blood volume to be collected will be approximately 51 mL (a little less than ¼ of a cup). As a reference, a standard blood donation is 470 mL in any 12-week period. You are advised not to donate any additional blood for 12 weeks after completing the study. As with all studies requiring blood donations, adequate rest and good eating habits are also advisable.

All blood samples taken in this research study will only be used for the purposes described in this document to analyse the study drug (Bicillin® L-A). Your blood samples will be stored in either the laboratory of the Sponsor, or the laboratory of a company contracted to work with the Sponsor for a period of up to 3 years. Access to study samples will be limited to laboratory personnel working for the Sponsor or who are contracted to work for the Sponsor, and authorised to perform analyses. Your name will not be present on any samples and the individual performing the testing will not know your identity, solely the participant number that you are assigned will be present.

You have the right to withdraw from this study at any time, however, information and samples that already have been collected from you may continue to be used.

Additional information you need to know:

If I am injured from the study drug, who will pay the doctor and hospital bills?

If you are injured as a result of your participation in this trial you may be entitled to compensation.

Sponsors of clinical trials in Australia have agreed that the guidelines developed by their industry body, Medicines Australia, will govern the way in which compensation claims from injured participants are managed by sponsors.

However, as guidelines, they do NOT in any way dictate the pathway you should follow to seek compensation. The sponsor is obliged to follow these guidelines.

These guidelines are available for your inspection on the Medicines Australia Website (www.medicinesaustralia.com.au) under Policy – Clinical Trials – Indemnity & Compensation Guidelines. Alternatively, your study doctor can provide you with a hard-copy of the guidelines.

It is the recommendation of the independent ethics committee responsible for the review of this trial that you seek independent legal advice before taking any steps towards compensation for injury.

What benefits could there be from taking part in the study?

There will be no clear benefit to you from your participation in this research. Information learned from the study may help other people in the future.

Are there alternatives to participation?

Since this study is intended only to test the effect of the study drug in healthy volunteers, your alternative to being a volunteer in this study is to choose not to participate in the study.

Will I receive a fixed payment per visit to cover any out of pocket expenses?

The payment for participants who participate in and complete this study will be $1,575.

If you are an alternate, the payment will be $75.

Participant payment is for your time, inconvenience and any minor discomfort you may have. Your travel expenses and parking costs have been factored into this payment.

If you choose to withdraw your consent to participate in the study, then the level of payment you will receive will be on a pro-rata basis. (i.e. you will receive a partial payment). You should also be aware that your study payment may be reduced or forfeited if you fail to follow any of the restrictions specified in this Participant Information Sheet. You will receive partial payment if you are withdrawn from the study due to non-medical reasons. You will receive full payment if you are withdrawn from the study because of medical reasons or a medical event related to the study.

Voluntary participation / Withdrawal from the study

Your participation in this study is purely voluntary. You may refuse to take part or withdraw from this study at any time without penalty or loss of benefits to which you are otherwise entitled. You may be withdrawn from the study if the study doctor feels it is best for you or if you do not comply with the requirements of the study. The Sponsor or the study doctor can also stop this study at any time for clinical or administrative reasons without regards to the participant consent.

If you wish to withdraw from the study while staying in the clinical trial unit, please discuss this with the study staff who will assist you in this matter and ensure you are safe to leave.

Before you leave the study, the study doctor will want to examine you, measure your heart rate, blood pressure, respiratory rate and temperature and/or collect blood samples to check your general health.

Any significant new findings developed during the course of the research, which may affect your willingness to continue participation in this study, will be provided to you in a timely manner.

Termination of the Study

The research project may be stopped for a variety of reasons. These may include the following: unacceptable side effects and decisions made in the commercial interest of the sponsor.

How will my privacy be protected?

If you decide to be in this study, the study doctor and research team will use, with your permission, health data about you to conduct this study, as described in this consent form. This may include your name, address, phone number, medical history, date of birth, and information from your study visits. With your permission, this health data may come from your family doctor or other health care workers.

Please note that Linear does not sell any medications to the public and Linear personnel would never offer to sell any products to you. All medication provided by Linear for the purpose of the trial will always be free of charge to you.

By signing this document, you agree to allow the research team to share health data about you with government agencies and ethics committees that oversee the research, the Sponsor, and those working for the Sponsor, which may include affiliates of the Sponsor located in your country or other countries. An affiliate of the Sponsor includes all companies directly or indirectly owned by the Telethon Kids Institute. People who work for the Sponsor to make sure the study rules are followed will be able to see all health data about you at the study site.

The health data that is sent to the Sponsor and those working for the Sponsor will not identify you by name. Instead, it may include your initials, partial date of birth i.e. month and year, and study visit dates. You will not be identified by name in any published reports about this study or in any other scientific publication or presentation. If you think that you were harmed from being in the study, the study team may also share health data about you with the Sponsor's insurer to resolve your claim.

The Sponsor and those working for the Sponsor, which may include affiliates of the Sponsor, may use the health data sent to them:

- to see if the study drug has any side effects;
- how much of the study drug gets into the bloodstream and how long it takes to get rid of it;
- for other activities (such as development and submission to a regulatory authority like the TGA) related to the study drug.

For these uses, the Sponsor may share this health data with others involved in these activities, as long as they agree to only use the health data as described here. The Sponsor and those working for the Sponsor, which may include affiliates of the Sponsor, may transfer health data about you from your country to other countries where the privacy laws are not as strict. Once the research team shares health data about you with others, it may no longer be protected by privacy laws.

Your permission to use and share health data about you will not end.

You may take away your permission to use and share health data about you at any time by writing to the study doctor. If you do this, you will not be able to stay in this study. No new health data that identifies you will be gathered after that date. However, health data about you that has already been gathered may still be used and given to others as described in this form.

Your records relating to this study and any other information received will be kept strictly confidential. However staff participating in your care, the sponsor and other agencies authorised by law, may inspect the records related to the study. In the event you are admitted to hospital as a result of an adverse event resulting from this study, your treating doctor may require access to your study records.

Participants should note that, some data derived from your participation in this study will be sent overseas; the regulatory regimes government data access and use in other countries may not be the same as those that are in place in Australia. If you have any questions about this direct them to the Principal Investigator.

Your identity will not be revealed and your confidentiality will be protected in any reviews and reports of this study which may be published. However, results may be suppressed for commercial reasons as the sponsor of the project retains the rights to the data.

Linear Clinical Research has a privacy policy which can be made available to you should you wish to review it. It contains information about the use and disclosure of personal information relating to participants, and what Linear Clinical Research is required to do to maintain confidentiality of information.

Will information about this trial be included in a Registry Databank?

A description of this clinical trial will be available on the Australian New Zealand Clinical Trials Registry (anzctr.org.au), as required by the Declaration of Helsinki and the Australian National Statement on Ethical Conduct in Human Research 3.3.12. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this Web site at any time.

Who do I call if I have questions about…

- **The study or to report a study-related injury:** Linear Clinical Research Ltd. at (08) 6382 5100. The Sponsors, Telethon Kids Institute can be contacted on (08) 6319 1454 (office hours), or 0487 932 366, 24 hours a day for emergencies.
- **Your rights as a participant in the study:** The Bellberry Human Research Ethics Committee has reviewed and approved this study in accordance with the National Statement on Ethical Conduct in Human Research (2007) incorporating all updates. This Statement has been developed to protect the interests of people who agree to participate in human research studies. Should you wish to discuss the study or view a copy of the Complaint procedure with someone not directly involved, particularly in relation to matters concerning policies, information or complaints about the conduct of the study or your rights as a participant, you may contact the Operations Manager, Bellberry Limited on (08) 8361 3222.

PARTICIPANT INFORMED CONSENT FORM

Sponsor Protocol Number: U1111-1216-5903

Study Name: **Pharmacokinetics of Intramuscular Versus Subcutaneous Administration of Benzathine Penicillin G (Bicillin® L-A)**

Study Doctor: **A/Prof. Laurens Manning**

- I have read and understood this Participant Information Sheet and Informed Consent Form.
- I am male and aged between 18 to 65 years of age (inclusive) and have been given enough time to consider my participation and asked for advice if necessary.
- I have had the opportunity to ask questions and have received satisfactory answers.
- I understand that all of the information will be kept confidential and that the result will be used for scientific objectives.
- I authorise my research and medical records as they pertain to this study to be reviewed by the Sponsor, authorised representatives and other regulatory agencies as described in this consent form.
- I understand that my participation in this study is voluntary and that I am completely free to withdraw my consent or refuse to participate at any time without changing in any way the quality of care that I receive. If I decide to withdraw from the study, I agree that the information collected about me up to the point when I withdraw may continue to be processed.
- I understand that if I agree to leave the study for any reason, the study doctor may ask me to do some end-of-study tests.
- The nature and purpose of the research project and potential risks and discomforts associated with it have been explained to me. I understand them and agree to take part.
- I consent to my GP and /or treating specialist, should I have one, being notified of my participation in this study and of any clinically relevant information noted by the study doctor in the conduct of the study, and to be contacted to obtain information regarding my medical history.
- I confirm that I will provide, to the best of my knowledge, a full and accurate medical and surgical history and details of any current medical conditions and medicines I am taking.
- I agree to additional tests being conducted during the study, as requested by a study doctor, if the doctor has any concerns in relation to my health whilst on the study.
- I understand that Linear Clinical Research Ltd. is not connected with the Government of Western Australia, including Sir Charles Gairdner Hospital and that doctors involved in the conduct of this clinical study at the Linear Clinical Research Facility do so in a private capacity and not as employees of the state.
- I have been given a copy of the Participant Information Sheet. I am aware that I will receive a copy of this fully signed and dated Informed Consent Form.
- As a volunteer, I freely consent to participate in this study.

Participant's Name (printed): _____

Signature: _____ **Date:** __ __ / __ __ __ /__ __ __ __ **Time*:** ____ : ____

<u>Declaration by Investigator</u>: I have given a verbal explanation of the study, its procedures and risks and I believe that the participant has understood that explanation.

Investigator's Name (printed): _____

Signature: _____ **Date:** __ __ / __ __ __ / __ __ __ __ **Time:** ____ : ____

**** Participant must sign the consent form first, prior to the Investigator.***
Note: All parties signing the Consent Form must date their own signature.